AstraZeneca plc (ADR) (AZN) was Downgraded by Goldman to ” Sell”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on Apr 12, 2016.
Many Wall Street Analysts have commented on AstraZeneca plc (ADR). AstraZeneca plc (ADR) was Downgraded by Goldman to ” Sell” on Apr 12, 2016. AstraZeneca plc (ADR) was Downgraded by Jefferies to ” Hold” on Mar 15, 2016. AstraZeneca plc (ADR) was Initiated by Cantor Fitzgerald to “Buy” on Feb 26, 2016.
On the company’s financial health, AstraZeneca plc (ADR) reported $0.94 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 4, 2016. Analyst had a consensus of $0.91. The company had revenue of $6399.00 million for the quarter, compared to analysts expectations of $6295.66 million. The company’s revenue was down -4.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.76 EPS.
AstraZeneca plc (ADR) closed down -0.36 points or -1.22% at $29.09 with 30,83,169 shares getting traded on Monday. Post opening the session at $29.52, the shares hit an intraday low of $29.04 and an intraday high of $29.54 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).